Affimed N.V. (NASDAQ:AFMD) – Research analysts at Oppenheimer Holdings dropped their Q3 2017 earnings per share estimates for shares of Affimed N.V. in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst H. Singh now forecasts that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.18). Oppenheimer Holdings currently has a “Buy” rating and a $10.00 target price on the stock. Oppenheimer Holdings also issued estimates for Affimed N.V.’s Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($0.86) EPS and FY2018 earnings at ($0.85) EPS.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Affimed N.V. from a “buy” rating to a “hold” rating in a report on Friday, April 21st. SunTrust Banks, Inc. started coverage on shares of Affimed N.V. in a research report on Thursday, July 13th. They set a “buy” rating and a $7.00 target price for the company. Jefferies Group LLC boosted their target price on shares of Affimed N.V. to $2.50 and gave the company a “hold” rating in a research report on Wednesday, April 26th. Finally, ValuEngine upgraded shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Affimed N.V. has an average rating of “Hold” and an average target price of $4.80.

TRADEMARK VIOLATION NOTICE: “Affimed N.V. (NASDAQ:AFMD) to Post Q3 2017 Earnings of ($0.19) Per Share, Oppenheimer Holdings Forecasts” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/06/affimed-n-v-nasdaqafmd-to-post-q3-2017-earnings-of-0-19-per-share-oppenheimer-holdings-forecasts.html.

Affimed N.V. (NASDAQ AFMD) opened at 2.10 on Friday. The company’s market capitalization is $92.27 million. The company has a 50-day moving average price of $2.22 and a 200-day moving average price of $2.23. Affimed N.V. has a one year low of $1.65 and a one year high of $3.25.

Affimed N.V. (NASDAQ:AFMD) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.02. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The company had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $1.31 million. During the same period last year, the firm earned ($0.24) EPS. Affimed N.V.’s revenue for the quarter was down 75.4% compared to the same quarter last year.

A number of hedge funds and other institutional investors have recently bought and sold shares of AFMD. Creative Planning raised its stake in shares of Affimed N.V. by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 15,000 shares during the period. NEA Management Company LLC purchased a new stake in shares of Affimed N.V. during the first quarter valued at about $8,944,000. Wellington Management Group LLP raised its stake in shares of Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 1,274,852 shares during the period. Nationwide Fund Advisors raised its stake in shares of Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 479,007 shares during the period. Finally, Tekla Capital Management LLC raised its stake in shares of Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock valued at $3,232,000 after buying an additional 1,111,111 shares during the period. Institutional investors own 42.41% of the company’s stock.

About Affimed N.V.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Earnings History and Estimates for Affimed N.V. (NASDAQ:AFMD)

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.